Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Q2 2026 financial results for period ended June 30, 2026.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for period ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive earnings details
Item 7.01 · Regulation FD Disclosure
- Presentation materials furnished as Exhibit 99.2 under Item 7.01 Regulation FD disclosure
- Materials posted on Indivior’s website August 3, 2026
- Investor-relevant details contained in Exhibit 99.2 and the company website
Item EX-99.1 · Exhibit EX-99.2
- Q2 revenue $343M, up 14% YoY, led by SUBLOCADE revenue $253M, up 21%
- Adjusted EBITDA $186M, up 111%, while GAAP net income reached $122M versus $18M
- Raised FY2026 revenue guidance to $1.295B–$1.365B and adjusted EBITDA guidance to $700M–$740M
- Repurchased 4.7M shares for $175M in Q2, bringing year-to-date repurchases to $300M
- Proposed all-stock merger with Supernus expected in Q4, adding transaction-completion and integration risk to the outlook
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.